Payment overview · 2025
General Payments
$912.21
51 reported records · 16 companies
Healthcare provider profile · identity verified
Chad Edward Weldon, DO
Allopathic & Osteopathic Physicians|Family Medicine · GRANBURY, TX · NPI 1942520960
Verified facts
What the public records show
CMS Open Payments records show Chad Edward Weldon, DO received $912.21 in general payments during 2025 across 51 reported records.
Novo Nordisk Inc accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $192.44 | 21.1% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $167.22 | 18.3% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $164.49 | 18.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $97.95 | 10.7% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $64.58 | 7.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.04 | 3.3% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $24.84 | 2.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $22.25 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.15 | 2.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.15 | 2.3% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.00 | 2.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.80 | 2.2% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $18.48 | 2.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.80 | 1.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.90 | 1.6% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $14.12 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $912.21 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $164.49 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $141.20 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $118.91 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $113.51 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $97.95 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $89.37 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.57 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 50 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
109 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 489 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 252 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 243 | 70 |
| Gabapentin | Gabapentin | 241 | 65 |
| Montelukast Sodium | Montelukast Sodium | 233 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 224 | 49 |
| Losartan Potassium | Losartan Potassium | 220 | 61 |
| Lisinopril | Lisinopril | 216 | 63 |
| Fluticasone Propionate | Fluticasone Propionate | 192 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 51 |
| Simvastatin | Simvastatin | 171 | 42 |
| Trazodone Hcl | Trazodone Hcl | 171 | 43 |
| Metformin Hcl | Metformin Hcl | 170 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 30 |
| Furosemide | Furosemide | 153 | 40 |
| Omeprazole | Omeprazole | 153 | 39 |
| Metformin Hcl Er | Metformin Hcl | 134 | 38 |
| Potassium Chloride | Potassium Chloride | 125 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 45 |
| Allopurinol | Allopurinol | 121 | 31 |
| Bupropion Xl | Bupropion Hcl | 120 | 26 |
| Meloxicam | Meloxicam | 116 | 29 |
| Eliquis | Apixaban | 109 | 22 |
| Famotidine | Famotidine | 101 | 20 |
| Sertraline Hcl | Sertraline Hcl | 100 | 26 |
| Alprazolam | Alprazolam | 97 | 21 |
| Tramadol Hcl | Tramadol Hcl | 97 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 27 |
| Temazepam | Temazepam | 96 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 20 |
| Ramipril | Ramipril | 82 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 18 |
| Alendronate Sodium | Alendronate Sodium | 74 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 27 |
| Celecoxib | Celecoxib | 63 | 14 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Prednisone | Prednisone | 63 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 19 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 14 |
| Ozempic | Semaglutide | 59 | 16 |
| Mounjaro | Tirzepatide | 58 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 57 | 21 |
| Carvedilol | Carvedilol | 56 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 16 |
| Jardiance | Empagliflozin | 50 | 14 |
| Synthroid | Levothyroxine Sodium | 49 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 12 |
| Ezetimibe | Ezetimibe | 42 | 16 |
| Linzess | Linaclotide | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Azithromycin | Azithromycin | 39 | 32 |
| Atenolol | Atenolol | 38 | 13 |
| Buspirone Hcl | Buspirone Hcl | 37 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 12 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Etodolac | Etodolac | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | 11 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 24 |
| Ondansetron Odt | Ondansetron | 26 | 11 |
| Cephalexin | Cephalexin | 25 | 21 |
| Primidone | Primidone | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Humira Pen | Adalimumab | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Naproxen | Naproxen | 15 | 12 |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Rayos | Prednisone | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $912.21 · 51 records | Novo Nordisk Inc | ACCRUFER, AIRSUPRA, ARISTADA, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, EVENITY, JARDIANCE, LINZESS, LYBALVI, NURTEC ODT, Ozempic, PAXLOVID, Paradise Ultrasound Renal Denervation System, QULIPTA, Qelbree, REXULTI, Rybelsus, Senza, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error